1. Home
  2. ZYME vs EFC Comparison

ZYME vs EFC Comparison

Compare ZYME & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.56

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

EFC

Ellington Financial Inc.

HOLD

Current Price

$12.38

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZYME
EFC
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2022
2007

Fundamental Metrics

Financial Performance
Metric
ZYME
EFC
Price
$26.56
$12.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
5
Target Price
★ $38.90
$14.55
AVG Volume (30 Days)
514.3K
★ 1.1M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
★ 11.84%
EPS Growth
★ 33.33
N/A
EPS
N/A
★ 1.21
Revenue
★ $105,965,000.00
N/A
Revenue This Year
$183.10
N/A
Revenue Next Year
N/A
$43.05
P/E Ratio
★ N/A
$10.22
Revenue Growth
★ 38.87
N/A
52 Week Low
$16.00
$11.28
52 Week High
$31.34
$14.12

Technical Indicators

Market Signals
Indicator
ZYME
EFC
Relative Strength Index (RSI) 47.51 30.64
Support Level $22.10 $12.37
Resistance Level $27.30 $13.76
Average True Range (ATR) 0.99 0.21
MACD -0.19 -0.05
Stochastic Oscillator 24.20 16.19

Price Performance

Historical Comparison
ZYME
EFC

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. It acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

Share on Social Networks: